AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, ...
Attendees will gain insights into the NanoKnife System’s proprietary irreversible electroporation (IRE) technology and how it is poised to become the standard, function-preserving treatment for men ...
AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target and destroy tissue without delivering excess heat and the unintended ...
The clearance for the NanoKnife System for prostate tissue ... ablating prostate tissue in patients with intermediate-risk prostate cancer (PCa). The latest regulatory clearance is a significant ...
It is worthwhile to note that the PRESERVE clinical study assessed the safety and effectiveness of the NanoKnife System for ablating prostate tissue in patients with intermediate-risk prostate cancer ...
Hosted on MSN29d
NanoKnife gains FDA clearance for prostate tissue ablationAngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer patients. The system, which was already FDA-cleared for the surgical ...
The clearance is supported by data from the PRESERVE trial (NCT04972097), which evaluated the safety and effectiveness of the NanoKnife System in ablating prostate tissue in patients with intermediate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback